Physician profile
Curtis D Schultz
NPI 1477572212
$248.11
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2021: $28.53 · 2022: $81.89.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $89.46 | 2019-2022 | |
| Abbvie INC. | $44.88 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $29.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $27.98 | 2019 | |
| Amarin Pharma, INC. | $18.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.99 | 2019 | |
| Lilly USA, LLC | $12.72 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.46 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.